Skip to main content
  • Contact

    Contact Sales

     

    Fill in the form to have a Dassault Systèmes expert contact you to answer your questions and discuss any of your needs or call directly on one of these numbers:

    USA & Canada: 1855 696 1125

    India: 1800 200 9276

    Other English countries: +800 379 78 361

    If you have any questions regarding our other services, please get in touch with:

    • our Technical & Customer support
    • our Academic team

     

  • Life Sciences & Healthcare

    • Challenges
      • Multifactorial Complex Diseases
      • Access to Science & Technology Breakthroughs
      • Patient Autonomy
      • Better Access to Care for All, Everywhere
      • Intense Competition, New Players
      • Data & Digitalization Imperative
      • Regulatory Pressure
      • The Sustainability Mandate
    • Segments
      • Pharmaceutical and Biotech
      • Medical Device
      • Patient Care
    • Solutions
    • Resources
      • Customer Stories
      • Events
      • Resource Center
  1. Life Sciences & Healthcare
  2. Industries
  3. 3DS
  1. Advancing a sustainable pharmaceutical manufacturing strategy

Advancing a sustainable pharmaceutical manufacturing strategy

Current pharmaceutical sustainability approaches aren’t sufficient to meet high sustainability requirements, but there is a better way.

Sustainability by design

According to a report by Accenture and Dassault Systèmes, the pharmaceutical industry’s greenhouse gas (GHG) emissions are increasing despite efforts to decarbonize. Analyses of emissions per million dollars of revenue find that the global pharmaceutical industry is approximately 55 percent more emissions-intensive than the automotive industry. This figure is only set to grow in tandem with the rising global demand for therapies.

Today, only 50 percent of the global population has access to essential healthcare, halfway to the United Nations’ goal of achieving 100 percent of universal coverage by 2040. Until then, the number of cancer and neurological degenerative diseases is expected to increase with global demographic growth.

“These complex multifactorial diseases are not easy to treat or cure, and pharmaceutical and biotechnology companies have adapted to this challenge by developing sophisticated therapies,” said Claire BIOT, Vice President of Life Sciences and Healthcare at Dassault Systèmes.

Novel therapies used to fight complex diseases are often based on biologic therapeutic ingredients involving either monoclonal antibodies, antibody fragments, recombinant proteins or even cell and gene therapies that have to be administered through injections or infusions. They tend to be produced in smaller batches as personalization of treatment progresses.

Claire BIOT
Life Sciences and Healthcare Industry Vice President, Dassault Systèmes

As pharmaceutical manufacturing lines transition towards small batch production to produce these precision medicines, manufacturers need to effect end-to-end manufacturing line optimizations to produce these therapies more sustainably.

However, many pharmaceutical companies have to consider the global scale of such an endeavor. Recent merger and acquisition activity in the pharmaceutical industry has resulted in companies acquiring a much larger global manufacturing footprint, requiring them to solve increasing complexity in their supply chains. These disparate systems, managing highly technical and scientific data do not communicate with each other, obstructing the acceleration of novel therapies.

Instead, sustainability needs to be factored into pharmaceutical manufacturing from the start. “It’s in the early phases of the design that you factor in the environmental, social and business sustainability requirements to be able to optimize them,” said Arnaud CASTÉRAN, a Senior Offer Marketing Manager at CATIA. To do so, pharmaceutical manufacturers need to transition to digitalized manufacturing to manufacture more sustainably.

The impact of sustainable pharmaceutical manufacturing

Pharmaceutical manufacturers need to adopt a new paradigm to optimize their complex industrial plants, processes and products. They need to digitalize their manufacturing because it is the only way to enable diverse stakeholders to come together and systematically determine, among many considerations:

  • Whether to construct new facilities or optimize existing ones
  • Where therapies should be produced
  • If it’s possible to increase resource efficiency and effect process improvements to lower costs
  • How to link patients to the product, process and factory

“All of these considerations can be factored into digitalized manufacturing with a process-based design so that pharmaceutical companies can produce what they expect from the start. The right science-based tools work seamlessly with digitalized manufacturing lines to enable the iterative loop that ensures pharmaceutical manufacturing can continue to manufacture sustainably from the first phase,” added Arnaud.

This strategy enables pharmaceutical manufacturers to positively impact:

  • Society, by balancing access, cost and quality needs to ensure equitable access to healthcare and medicine for all, across global markets. These considerations are proactive and include ensuring the functionality and integrity of therapeutic products and serialization across the production line.
  • The environment, by realizing clean operations and energy-efficient supply chains because manufacturers can quickly source sustainable raw materials, reduce waste and GHG emissions during production, and integrate more closely with the circular economy.
  • Business, by enabling pharmaceutical companies to confidently demonstrate global manufacturing compliance and integrity in a transparent and cost effective way that engenders trust and sustainable revenue generation.

The digital solution to manufacturing sustainability

Digital manufacturing is realized with a virtual twin, a digital replica of real-world pharmaceutical processes, products and plants from end-to-end. It delivers the agility manufacturers need with science-based tools that can be leveraged to develop novel therapies.

These tools adhere to scientific principles across biology, chemistry, physics and engineering, making them a crucial enabler in a science-based domain like pharmaceuticals. Then, the right platform unites diverse stakeholders, including designers, engineers, supply chain vendors, scientists, and others, with scientific data to accelerate decision-making, process intelligence and analysis. As a result, pharmaceutical manufacturers can experience unparalleled transparency levels to communicate regulatory compliance and build trust with regulators and patients.

The combination of the virtual twin and the power of the 3DEXPERIENCE® platform has a decades-long transformative effect in the manufacturing phase of many highly demanding technical industries like aerospace, high-tech and transportation. It’s now time for pharmaceutical companies to leverage best-in-class scientific tools to revolutionize their manufacturing lines and deliver innovative therapies while ensuring environmental, social and business sustainability.

Accelerate your journey to sustainable pharmaceutical manufacturing
Download our eBook to discover how you can realize sustainable pharmaceutical manufacturing with virtual twins and the 3DEXPERIENCE platform.

Download

Realize more sustainable pharmaceutical manufacturing today

You’ll discover a more agile and collaborative way to optimize manufacturing for novel therapies while meeting the high demands of the sustainability mandate.

Our eBook details the challenges faced and solutions available for you to realize more sustainable manufacturing and solve:

  • Societal demand for affordable and accessible high-quality therapeutics
  • Environmental concerns brought about by climate change
  • Business complexity due to rising global pharmaceutical demand and the need to generate revenue ethically

Download Now

We Can Do It For You

The transition to virtualizing your pharmaceutical manufacturing may be challenging for companies. That is why Dassault Systèmes can do it for you. Our experts can build a virtual twin of your facility, equipment and processes to help you revolutionize your manufacturing lines and deliver innovative therapies while ensuring environmental, social and business sustainability. 

Discover More
Solutions

Explore our Industry Solutions Experiences

Learn more about how our Industry Solutions can help you achieve your professional ambitions and business objectives.

Industry Solution Experience
Made to Cure for BioPharma

Boost agility and performance of your global manufacturing operations to produce high-quality medicines

Industry Solution Experience
License to Cure for BioPharma

Achieve enterprise-wide data integrity for total quality and compliance.

Industry Solution Experience
ONE Lab

Transform laboratory efficiency, compliance and collaboration for faster product and process development

Industry Solution Experience
Designed to Cure

Unify modelling & testing to accelerate the discovery of high-quality novel therapeutics

Share